New drug targets 'Undruggable' cancer driver in Tough-to-Treat lymphomas
NCT ID NCT07069699
Summary
This early-stage trial is testing a new drug called pidnarulex (CX-5461) in adults with aggressive, hard-to-treat B-cell lymphomas that have a specific genetic feature called MYC aberration. The main goals are to find the safest and most effective dose and to see if the drug can shrink tumors. The study will also look at how the drug works in the body and its effects on cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BURKITT LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yale University Cancer Center LAO
RECRUITINGNew Haven, Connecticut, 06520, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.